anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The clinical management of radiation-induced skin injury (RSI) poses a significant challenge, primarily due to the acute damage caused by an overabundance of reactive oxygen species (ROS) and the ongoing inflammatory microenvironment. Here, we designed a dual-network hydrogel composed of 5 % (w/v) Pluronic F127 diacrylate and 2 % (w/v) hyaluronic acid methacryloyl, termed the FH hydrogel. To confer antioxidant and anti-inflammation properties to the hydrogel, we incorporated PVP-modified Prussian blue nanoparticles (PPBs) and resveratrol (Res) to form PHF@Res hydrogels. PHF@Res hydrogels not only exhibited multiple free radical scavenging activities (DPPH, ABTS), but also displayed multiple enzyme-like activities (POD-, catalase). Meanwhile, PHF@Res-2 hydrogels significantly suppressed intracellular ROS and promoted the migration of fibroblasts in a high-oxidative stress environment. Moreover, in the RSI mouse model, the PHF@Res-2 hydrogel regulated inflammatory factors and collagen deposition, significantly reduced epithelial hyperplasia, promoted limb regeneration and neovascularization, and accelerated wound healing, outperforming the commercial antiradiation formulation, Kangfuxin. The PHF@Res-2 hydrogel dressing shows great potential in accelerating wound healing in RSI, offering tremendous promise for clinical wound management and regeneration.
The invention belongs to the field of traditional Chinese medicine preparations and provides a pharmaceutical preparation capable of treating chronic glomerulonephritis. The pharmaceutical preparation is prepared from, by weight, 25 parts of flabelate maiden-hair herb, 18 parts of rabdosia japonica (Burm.f.) Hara var. glaucocalyx (Maxim.) Hara, 20 parts of Chinese eurya roots, 30 parts of roots or leaves of redback christmashush, 20 parts of hairyvein agrimonia herb, 15 parts of common macrocarpium fruit, 10 parts of milkvetch roots, 25 parts of Indian buead, 18 parts of Chinese yam, 25 parts of prepared rehmannia roots, 12 parts of Chinese taxillus twigs,  12 parts of lalang grass rhizomes, 30 parts of Chinese angelica, 15 parts of cattail pollen, 30 parts of motherwort herb, 30 parts of hiraute shiny bugleweek herb, 15 parts of ramulus uncariae cum uncis, 20 parts of yerbadetajo herb, 20 parts of dwarf lilyturf tubers, 10 parts of bidentate achyranthes roots, 10 parts of amur corktree bark and 10 parts of liquorice. The pharmaceutical preparation is capable of treating the chronic glomerulonephritis.
Stroke survivors receiving the OnTrack intervention for 12 weeks consisting of arm activity tracking and self-management coaching. Assessments are done before and after the intervention.
Compositions and methods for treating or preventingE. coliinfections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduceE. colipopulations and thereby treat or prevent infection byE. coli. The compositions include one or more digestive enzymes, e.g., one or more protease, lipases, and amylases. Methods of use of the compositions are also provided.
There are four conditions in the experiment. All condition will be presented, randomly mixed in a single block of 400 trials (with breaks every 100 trials).
PURPOSE: The poor visual outcomes associated with fungal keratitis (FK) underscore a need to identify fungal pathways that can serve as novel antifungal targets. In this report, we investigated whether hypoxia develops in the FK cornea and, by extension, if fungal hypoxia adaptation is essential for virulence in this setting.
METHODS: C57BL/6J mice were inoculated with Aspergillus fumigatus and Fusarium solani var. petroliphilum via topical overlay or intrastromal injection. At various time points post-inoculation (p.i.), animals were injected with pimonidazole for the detection of tissue hypoxia through immunofluorescence imaging. The A. fumigatus srbA gene was deleted through Cas9-mediated homologous recombination and its virulence was assessed in the topical infection model using slit-lamp microscopy and optical coherence tomography (OCT).
RESULTS: Topical inoculation with A. fumigatus resulted in diffuse pimonidazole staining across the epithelial and endothelial layers within 6 hours. Stromal hypoxia was evident by 48 hours p.i., which corresponded to leukocytic infiltration. Intrastromal inoculation with either A. fumigatus or F. solani similarly led to diffuse staining patterns across all corneal cell layers. The A. fumigatus srbA deletion mutant was unable to grow at oxygen levels below 3% in vitro, and corneas inoculated with the mutant failed to develop signs of corneal opacification, inflammation, or fungal burden.
CONCLUSIONS: These results suggest that fungal antigen rapidly drives the development of corneal hypoxia, thus rendering fungal SrbA or related pathways essential for the establishment of infection. Such pathways may therefore serve as targets for novel antifungal intervention.
The experimental group will receive treatment as usual, in addition to training with the Jintronix platform. Participants will undergo their prescribed therapy regimen for 3 months, with outcomes follow-up to 12 months post-discharge.
PURPOSE:To obtain the subject drug exhibiting remarkable hypnotic and sedative effects and useful in medical field as a solid peroral drug by using an extract of Passiflora incarnata (a kind of passion flower) and an antihistaminic substance as active components. CONSTITUTION:The objective agent contains an extract of Passiflora incarnata and an antihistaminic substance as active components. The antihistaminic substance is e.g. diphenhydramine hydrochloride, diphenhydramine salicylate and diphenhydramine tannate. The weight ratio of the extract of Passiflora incarnata to the antihistaminic substance is about 2-10,000. It is preferably administered in the form of a solid peroral drug such as tablet or capsule. The amount of the active component in the drug preparation is about 10-30wt.%.
This study will be conducted in healthy male or female subjects using a double-blind, randomized, placebo-controlled, single-dose design. Up to 30 subjects will be enrolled; 3 healthy subjects in Cohorts 1 and 2 (2 active, 1 placebo) and 8 healthy subjects in Cohorts 3 to 5 (6 active, 2 placebo). The following CPSI-2364 doses are proposed: 1 mg, 10 mg, 30 mg, 90 mg, and 270 mg. In Cohort 1 (1 mg) and Cohort 2 (10 mg), the three subjects will all be dosed on the same day, with at least 60 minute intervals between dosing. In Cohorts 3 to 5, the first two subjects of each cohort (one active, one placebo) will receive their drug on the same day with at least a 60-minute interval between dosing, with the remainder of the cohort being dosed the next day once these subjects have been assessed. Safety labs, physical examination findings, and adverse events available up to and including Day 5 data of each cohort will be reviewed by the Investigator, the Study Manager, and the Sponsor (or designee) in order to determine the progression of dose escalation. Subjects will not be enrolled in the next higher cohort until the dose in the preceding cohort is deemed safe and tolerable. Doses will continue to be escalated in subsequent groups until a maximum tolerated dose (MTD) is reached, or until a top dose of 270 mg is reached, whichever is sooner. Intermediate and repeat dose levels may be administered in addition to or in place of the planned dose levels, if it is deemed appropriate to increase the safety or scientific value of this Phase 1 exploratory study.Safety will be evaluated throughout the study and include physical examinations, vital signs assessments, 12-lead electrocardiograms (ECGs), routine clinical laboratory tests (including blood chemistry, hematology, coagulation, and urinalysis), and adverse event (AE) assessments. Vital sign assessments and 12-lead ECGs will be performed repeatedly over the 24-hour observation period.Venous blood samples will be taken at specified intervals and tested for the presence of CPSI-2364.
The invention belongs to the functions and the application field of genes and albumen, and relates to a target for screening and restraining the transfer of nasopharyngeal carcinoma by using Flotillin-2 as a medicine and application of the target. The invention provides the target for screening and restraining the transfer of the nasopharyngeal carcinoma, and the target is the Flotillin-2. The invention also provides the application of the Flotillin-2 as the medical target in the medicine for screening and restraining the transfer of the nasopharyngeal carcinoma. The invention also provides the medicine for restraining the transfer of the nasopharyngeal carcinoma by using the Flotillin-2 as the target. The medicine is siRNA of Flotillin-2. The invention firstly reveals the relationship between Flotillin-2(Flot2) and a TGF-beta signal route in the nasopharyngeal carcinoma and the effect of the Flotillin-2(Flot2) and the TGF-beta signal route in the transfer of the nasopharyngeal carcinoma. The Flot2 is an independent predictive factor for the poor prognosis of a patient in the nasopharyngeal carcinoma, is an important constituent part of the TGF-beta route, and is an indispensable important node in the process of promoting EMT. The silent Flot2 may become one of important means for opposing the EMT caused by TGF-beta. Therefore, the invention provides a theory basis and a clinical base for researching new target points and new policies for restraining the transfer of the nasopharyngeal carcinoma.
<P>PROBLEM TO BE SOLVED: To provide a new method and a composition for treating injury of mammalian spinal cord.  <P>SOLUTION: In order to achieve in vivo restoration of injured mammalian nervous tissue, an effective amount of a biomembrane fusion bonding agent as amphiphilic polymer is given to the injured nervous tissue. Application of the biomembrane fusion bonding agent can be performed by bringing the material into direct contact with the nervous tissue of the site of injury. Alternatively, the biomembrane fusion bonding agent can be delivered to the site of injury by blood supply after administration of the biomembrane fusion bonding agent to a patient. Preferably, the administration is parenteral administration of an effective amount of biomembrane fusion bonding agent including intravascular, intramuscular, subcutaneous or intraperiotoneal injection. As a result, the effective amount is delivered to the site of injury of the nervous tissue.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Participants received evolocumab 420 mg once a month subcutaneously using an automated mini-doser (AMD) (one 3.5 mL injection) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
PURPOSE:To enable effective separation of components within a red blood cell as intact, by injecting a red blood cell laked liquid obtained from a subtreatment of red blood cells into a suction or pressure type filter to separate components in the red blood cells of the red blood cell laked liquid from red blood cell membrane components with a filter film. CONSTITUTION:For a subtreatment of human red blood cells after a cleaning, 10mM of phosphoric acid or distilled water is mixed thereinto at a capacity ratio of 4:1 per red blood cells and stirred up. After a human red blood cell laked liquid is left alone under the temperature of 4 deg.C for 10 minute, it is inject ed into a Seitz type filter. The filter therein used shall be of a suction type which is provided with a cylindrical socket 1 into which the red blood cell laked liquid is injected, a funnel 2, an asbesto filtration film 5 sandwitched between flanges 3 and 4 of the both, a container 6 set in airtight contact with the funnel 3 and an electric pump 8 connected to the container 6 through a pipe 7. The filtration with the filter thus arranged provides a filtrate sterilized. Thus, the separation and removal of red blood cell film components form the human red blood laked blood can be achieved in a short time while components in the red blood cells can be separate as intact and under sterile conditions.
The invention provides a novel resveratrol derivative and a salt thereof, and an application of the resveratrol derivative and the salt thereof in preparing a drug for resisting alzheimer's disease. Experiments demonstrate that the resveratrol derivative has a significant suppreshing effect on aggregation of beta-amyloid protein (A[beta]) and has very strong capacities for removing oxygen radicals and resisting oxidation. Besides, the resveratrol derivative can chelate biological metal ions, and is a multi-targeted drug molecular for resisting the alzheimer's disease. The resveratrol derivative is shown as a formula I and a formula II. In the formula I and the formula II, R1, R2, R3, R4 and R5 are defined as the description. The formula I and the formula II are shown in the description.
BACKGROUND/AIM: The severe malignancy of pancreatic ductal adenocarcinoma (PDAC) is mainly due to frequent local invasiveness and distant metastasis. As for local invasiveness, we previously reported that cancer-specific molecular alterations detected on resected PDAC specimen surfaces, so-called molecular surgical margin (MSM) positiveness, were significantly associated with postoperative locoregional recurrence and distant metastasis. However, due to anatomical limitations, achieving adequate surgical margins during pancreatic cancer resection is often challenging. Therefore, predicting local invasiveness based on the primary tumor's gene profile is crucial to avoid positive MSM.
MATERIALS AND METHODS: Genome-wide miRNA expression profiles were examined and compared between MSM-positive and negative cases. Candidate miRNAs were evaluated in another validation cohort, and their clinicopathological characteristics were examined. Mimic or inhibitor constructs of the candidate miRNA were transfected to PDAC cell lines to evaluate the miRNA function in the pancreatic cancer cell lines and detect the downstream targets.
RESULTS: Among some candidates with highly expressed miRNAs in MSM-positive cases by miRNA expression array, recurrence-free survival (RFS) was significantly shorter in the miR-210-3p high expression group (p=0.015). High miR-210-3p was significantly associated with large tumor diameter (p=0.001), anterior invasion positive (p=0.010), and positive lymph node metastasis (p<0.001). miR-210-3p inhibition in PDAC cell lines resulted in decreased proliferation and invasiveness. The iron-sulfur cluster assembly enzyme (ISCU) gene was identified as a target of miR-210-3p. ISCU reduction was significantly observed in PDAC primary tumors with high levels of miR-210-3p, leading to mitochondrial dysfunction in miR-210-3p-overexpressing PDAC cell lines, as demonstrated by glycolysis stress tests.
CONCLUSION: Highly expressed hypoxia-inducible miR-210-3p in primary PDAC tissues induces locally invasive characteristics through mitochondrial dysfunction by suppressing ISCU expression, which may result in poor postoperative RFS outcomes.
Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), also known as post-COVID-19 condition or post-COVID syndrome, can affect anyone infected with SARS-CoV-2, regardless of age or the severity of the initial symptoms of COVID-19. Long COVID/PASC is the continuation or development of new symptoms after three months from the initial SARS-CoV-2 infection, which lasts for at least two months and has no other identifiable cause. Long COVID/PASC occurs in 10-20% of patients infected with SARS-CoV-2. The most common symptoms include fatigue, cognitive impairment (brain fog), and shortness of breath. However, more than 200 symptoms have been reported. No phenotypic or diagnostic biomarkers have been identified for developing long COVID/PASC, which is a multisystem disorder that can present with isolated or combined respiratory, hematological, immunological, cardiovascular, and neuropsychiatric symptoms. There is no cure. Therefore, individualized patient management requires a multidisciplinary clinical approach. Because millions of people have had and continue to have COVID-19, even in the era of vaccination and antiviral therapies, long COVID/PASC is now and will increasingly become a health and economic burden that the world must prepare for. Almost five years from the beginning of the COVID-19 pandemic, this article aims to review what is currently known about long COVID/PASC, the anticipated increasing global health burden, and why there is still an urgent need to identify diagnostic biomarkers and risk factors to improve prevention and treatment.
INTRODUCTION: Due to the COVID-19 pandemic, France underwent several lockdown periods during 2020. Our aim was to evaluate its clinical and social impact on lung transplant (LT) patients treated at Strasbourg University Hospital, by comparing three periods: first lockdown (T1: March-May 2020), end of the first lockdown (T2: May-October 2020), and second lockdown (T3: November-December 2020) and the incidence of COVID-19 infections. A cohort of patients with rare lung disease (RLD) was also studied during T2.
METHODS: We used clinical and paraclinical data collected during routine follow-up. A questionnaire was submitted to each patient at each period to assess their lifestyle, adherence to protective measures against COVID-19, contacts with their family and friends, and contagion risk. The incidence of new COVID-19 cases was also assessed.
RESULTS: Overall, 283 LT and 57 RLD patients were included. We observed only eight COVID-19 cases over the three periods (n = 4 during T1, n = 0 during T2, and n = 4 during T3) in LT patients, with 37.5 % of patients hospitalized, no ICU transfers, and 100 % favorable outcomes. No case of COVID-19 was diagnosed in the RLD cohort. When comparing the three periods in the LT group, fewer patients limited their out-of-home activities during T2 (p < 0.0001). The frequency of these activities increased after the first lockdown, for the purchase of basic necessities (p < 0.0001), and professional activity continued (p = 0.008). We observed a significant increase in unscheduled medical consultations and in the prescription of anti-infective treatments during the end of the lockdown (p = 0.0002 and p = 0.005, respectively). Adherence to lockdown and to protective measures was high in both groups of patients.
CONCLUSION: COVID-19 incidence remained low in both groups and there were significant lifestyle evolutions in LT patients and in those with RLD between first and second lockdown.
BACKGROUND: Fibromyalgia (FM) is a complex disorder with widespread pain and emotional distress, posing diagnostic challenges. FM patients show altered cognitive and emotional processing, with a preferential allocation of attention to pain-related information. This attentional bias towards pain cues can impair cognitive functions such as inhibitory control, affecting patients' ability to manage and express emotions. Sentiment analysis using large language models (LLMs) can provide insights by detecting nuances in pain expression. This study investigated whether open-source LLM-driven sentiment analysis could aid FM diagnosis.
METHODS: 40 patients with FM, according to the 2016 American College of Rheumatology Criteria and 40 non-FM chronic pain controls referred to rheumatology clinics, were enrolled. Transcribed responses to questions on pain and sleep were machine translated to English and analysed by the LLM Mistral-7B-Instruct-v0.2 using prompt engineering targeting FM-associated language nuances for pain expression ('prompt-engineered') or an approach without this targeting ('ablated'). Accuracy, precision, recall, specificity and area under the receiver operating characteristic curve (AUROC) were calculated using rheumatologist diagnosis as ground truth.
RESULTS: The prompt-engineered approach demonstrated accuracy of 0.87, precision of 0.92, recall of 0.84, specificity of 0.82 and AUROC of 0.86 for distinguishing FM. In comparison, the ablated approach had an accuracy of 0.76, precision of 0.75, recall of 0.77, specificity of 0.75 and AUROC of 0.76. The accuracy was superior to the ablated approach (McNemar's test p<0.001).
CONCLUSION: This proof-of-concept study suggests LLM-driven sentiment analysis, especially with prompt engineering, may facilitate FM diagnosis by detecting subtle differences in pain expression. Further validation is warranted, particularly the inclusion of secondary FM patients.
An exemplary embodiment providing one or more improvements includes feeding animals with probiotic microbes encapsulated in a mixture of xanthan gum and chitosan, or in gelatin, specifically  Pediococcus acidilactici  and  Saccharomyces boulardii.  Such encapsulation protects the viability of the probiotic microbes against unfavorable temperatures. An exemplary embodiment providing one or more improvements includes methods of using viable probiotics in therapy of birds and mammals infected with infectious diseases. Probiotics acted as adjuvants in stimulating antibody reaction and stimulated a cellular immunity response. In particular, probiotics were shown to reduce the number of viable oocytes from fecal samples, stimulate antibody production, and stimulate of proliferation of splenocytes in chickens infected with  Elimeria.  In addition, probiotics were shown to relieve symptoms of parvovirus infection in dogs.
The invention discloses a traditional Chinese medicine acne-removing extraction liquid and an acne-removing paste prepared with the extraction liquid. The traditional Chinese medicine acne-removing extraction liquid is prepared from the raw materials of, by weight, 5-25 parts of lightyellow sophora root, 2-13 parts of golden thread, 5-15 parts of dahurian patrinia herb, 5-25 parts of glabrous greenbrier rhizome, 5-15 parts of Philippine violet herb, 5-15 parts of dandelion, 5-15 parts of wild dendranthema flower, 2-8 parts of aloe, 5-15 parts of Chinese rose flower, and 5-15 parts of ligusticum. According to the traditional Chinese medicine acne-removing extraction liquid, according to a monarch, minister, assistant, and guide medicine theory in traditional Chinese medical science, the lightyellow sophora root, golden thread, dahurian patrinia herb, and glabrous greenbrier rhizome are adopted as monarch medicines. The medicines provide heat clearing, blood cooling, dampness eliminating, and itching relieving effects.Dandelion, wild dendranthema flower, and Chinese rose flower are adopted as minister medicines, and provide functions of liver soothing, depression relieving, detoxifying, and sore converging. Aloe is adopted as the assistant medicine, and provides the functions of bowel relieving, heat clearing, oil removing, and skin soothing. Wild dendranthema flower and ligusticum are adopted as guide medicines, and provide functions of qi promoting, blood activating, blood cooling, swelling subsiding, and tissue regeneration promoting.
After 2 hours from I-AT was performed the alternative AT by CPAP ventilation mode. Before CPAP-AT and 10 minutes after blood samples for arterial blood gases (ABG) were collected. If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%, CPAP-AT was aborterd.